Tags

Type your tag names separated by a space and hit enter

Novel treatment of Refractory/recurrent Pulmonary Hepatoblastoma.

Abstract

BACKGROUNDS

There is no consensus about how to manage pulmonary metastasis in patients with hepatoblastoma. Here, among our institution, we reviewed a treatment with a combination of Oxaliplatin/Vincristine/Topotecan(OVT) paired with radiofrequency ablation (RFA) of twelve patients with multiple refractory/recurrent pulmonary hepatoblastoma(HB).

METHODS

The medical records from patients with≤ 21 years of age presenting of multiple deposits (≥2) of refractory/recurrent pulmonary HB were reviewed. The following data were extracted from each patient, age, gender, histological subtyping, cycles of OVT, tumor size, biomarkers, chemotherapy regimen and dosage, RFA details, treatment response, follow up and patient outcomes. The primary outcome measure was the rate of complete response of pulmonary diseases, and secondary outcomes were event-free survival rate and overall survival rate.

RESULTS

Of twelve assessable patients, three (25%) (95%CI, 46.3% to 104%) patients achieved PR after they finished OVT. After RFA, five (41.7%) (95%CI, 8.95% to 74.4%) patients achieved CR. The 2-year EFS was 33% (95%CI, 20.5% to 64.6%). The 2-year OS for the study group was 41.7% (95%CI, 8.9% to 74.4%). All toxicity events were handled satisfactorily and no toxic related death were observed.

CONCLUSIONS

Our review report shows that OVT combined with RFA can be a successful treatment modality for previously heavily treated refractory/recurrent pulmonary metastatic lesions from hepatoblastoma.

Authors+Show Affiliations

Department of Pediatric Oncology, the First Hospital of Jilin University, Changchun, Jilin, China.Department of Pediatric Oncology, the First Hospital of Jilin University, Changchun, Jilin, China.Department of ultrasound, the First Hospital of Jilin University, Changchun, Jilin, China.Department of Pediatric respiratory, the First Hospital of Jilin University, Changchun, Jilin, China.Department of Pediatric Oncology, the First Hospital of Jilin University, Changchun, Jilin, China.Department of oncology, the First Hospital of Jilin University, Changchun, Jilin, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31885124

Citation

Zhang, Yu-Tong, et al. "Novel Treatment of Refractory/recurrent Pulmonary Hepatoblastoma." Pediatrics International : Official Journal of the Japan Pediatric Society, 2019.
Zhang YT, Chang J, Yao YM, et al. Novel treatment of Refractory/recurrent Pulmonary Hepatoblastoma. Pediatr Int. 2019.
Zhang, Y. T., Chang, J., Yao, Y. M., Li, Y. N., Zhong, X. D., & Liu, Z. L. (2019). Novel treatment of Refractory/recurrent Pulmonary Hepatoblastoma. Pediatrics International : Official Journal of the Japan Pediatric Society, doi:10.1111/ped.14134.
Zhang YT, et al. Novel Treatment of Refractory/recurrent Pulmonary Hepatoblastoma. Pediatr Int. 2019 Dec 30; PubMed PMID: 31885124.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel treatment of Refractory/recurrent Pulmonary Hepatoblastoma. AU - Zhang,Yu-Tong, AU - Chang,Jian, AU - Yao,Yun-Ming, AU - Li,Ya-Nan, AU - Zhong,Xiao-Dan, AU - Liu,Zi-Ling, Y1 - 2019/12/30/ PY - 2019/12/31/entrez KW - chemotherapy KW - hepatoblastoma KW - pediatric KW - radiofrequency ablation JF - Pediatrics international : official journal of the Japan Pediatric Society JO - Pediatr Int N2 - BACKGROUNDS: There is no consensus about how to manage pulmonary metastasis in patients with hepatoblastoma. Here, among our institution, we reviewed a treatment with a combination of Oxaliplatin/Vincristine/Topotecan(OVT) paired with radiofrequency ablation (RFA) of twelve patients with multiple refractory/recurrent pulmonary hepatoblastoma(HB). METHODS: The medical records from patients with≤ 21 years of age presenting of multiple deposits (≥2) of refractory/recurrent pulmonary HB were reviewed. The following data were extracted from each patient, age, gender, histological subtyping, cycles of OVT, tumor size, biomarkers, chemotherapy regimen and dosage, RFA details, treatment response, follow up and patient outcomes. The primary outcome measure was the rate of complete response of pulmonary diseases, and secondary outcomes were event-free survival rate and overall survival rate. RESULTS: Of twelve assessable patients, three (25%) (95%CI, 46.3% to 104%) patients achieved PR after they finished OVT. After RFA, five (41.7%) (95%CI, 8.95% to 74.4%) patients achieved CR. The 2-year EFS was 33% (95%CI, 20.5% to 64.6%). The 2-year OS for the study group was 41.7% (95%CI, 8.9% to 74.4%). All toxicity events were handled satisfactorily and no toxic related death were observed. CONCLUSIONS: Our review report shows that OVT combined with RFA can be a successful treatment modality for previously heavily treated refractory/recurrent pulmonary metastatic lesions from hepatoblastoma. SN - 1442-200X UR - https://www.unboundmedicine.com/medline/citation/31885124/Novel_treatment_of_Refractory/recurrent_Pulmonary_Hepatoblastoma L2 - https://doi.org/10.1111/ped.14134 DB - PRIME DP - Unbound Medicine ER -